Please use this identifier to cite or link to this item: https://has.hcu.ac.th/jspui/handle/123456789/3345
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIntthira Thiangkrathok-
dc.contributor.authorNattha Laobankho-
dc.contributor.authorThunpitcha Pilasopa-
dc.contributor.authorPhurit Thanarangsarit-
dc.contributor.authorอินทิรา เที่ยงกระโทก-
dc.contributor.authorณัฐฐา เหล่าบ้านค้อ-
dc.contributor.authorธัญพิชชา พิลาโสภา-
dc.contributor.authorภูริต ธนะรังสฤษฏ์-
dc.contributor.otherHuachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciencesen
dc.contributor.otherHuachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciencesen
dc.contributor.otherHuachiew Chalermprakiet University. Faculty of Pharmaceutical Sciences. Student of Bachelor of Pharmaceutical Sciencesen
dc.contributor.otherHuachiew Chalermprakiet University. Faculty of Pharmaceutical Sciencesen
dc.date.accessioned2024-12-04T11:53:47Z-
dc.date.available2024-12-04T11:53:47Z-
dc.date.issued2024-
dc.identifier.urihttps://has.hcu.ac.th/jspui/handle/123456789/3345-
dc.descriptionProceedings of the 11th National and International Conference on "Research to Serve Society", 26 June 2024 at Huachiew Chalermprakiet University, Bangphli District, Samutprakarn, Thailand. p. 475-482.en
dc.description.abstractThe aim of this study is to develop a secondary standard of favipiravir from favipiravir tablets for a replacement of costly reference standard. Firstly, favipiravir was isolated and purified from the powdered tablets by liquid-liquid extraction method using ethyl acetate and water. The total amount of extracted favipiravir yield 31.25% and the extract was consequently identified using Fourier-transform infrared (FT-IR) spectroscopy. Secondly, quantity or purity of extracted favipiravir was determined using a validated ultraviolet (UV)-visible spectrophotometric method. The analysis result showed that the purity of favipiravir was 95.98% (as is) which the acceptance criteria has been limited within 98.0-102.0%. Unfortunately, although the purity of developed favipiravir secondary standard was nearly met the criteria, it could be preliminary used as a standard substance in some routine pharmaceutical laboratory procedures, such as identification, in-process quality control, including pharmacological studies.en
dc.language.isoen_USen
dc.rightsมหาวิทยาลัยหัวเฉียวเฉลิมพระเกียรติen
dc.subjectSecondary Standarden
dc.subjectสารมาตรฐานทุติยภูมิen
dc.subjectFavipiraviren
dc.subjectฟาวิพิราเวียร์en
dc.subjectCOVID-19 (Disease)en
dc.subjectโควิด-19 (โรค)en
dc.subjectCOVID-19 Pandemic, 2020-en
dc.subjectการระบาดใหญ่ของโควิด-19, ค.ศ. 2020-en
dc.subjectUV-visible spectrophotometryen
dc.subjectอัลตราไวโอเลต-วิสิเบิลเสปกโทรโฟโตมิเตอร์en
dc.titleDevelopment of Favipiravir Secondary Standard from Favipiravir Tabletsen
dc.typeProceeding Documenten
Appears in Collections:Pharmaceutical Sciences - Proceeding Document

Files in This Item:
File Description SizeFormat 
Development of Favipiravir Secondary Standard.pdf332.17 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.